Agranulocytosis Following COVID-19 Recovery
Open Access
- 29 July 2020
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 12 (7) , e9463
Abstract
Clinicians have continued to report on the clinical behavior and characteristics of patients with coronavirus disease 2019 (COVID-19) as our knowledge of the virus continues to mature. Herein, we report the case of a 39-year-old male with multiple comorbidities who became critically ill with COVID-19 infection, requiring mechanical ventilation and vasopressors, and then developed agranulocytosis following clinical improvement and resolution of symptoms of COVID infection. The period of agranulocytosis coincided with the development of thrombocytosis, and following resolution of agranulocytosis, the platelet count also normalized, suggesting a possible related mechanism. Interestingly, the patient was treated with TBO-filgrastim 480 mcg daily with a rapid reconstitution of neutrophils. While the mechanism of agranulocytosis remains unknown, we report, to our knowledge, the first known case of agranulocytosis following COVID-19 infection and its successful treatment with granulocyte colony-stimulating factor.Keywords
This publication has 6 references indexed in Scilit:
- Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive studySignal Transduction and Targeted Therapy, 2020
- SARS-CoV-2 invades host cells via a novel route: CD147-spike proteinbioRxiv, 2020
- Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritisEuropean Journal of Rheumatology, 2019
- Expression of EMMPRIN (CD147) on circulating platelets in vivoJournal of Thrombosis and Haemostasis, 2010
- Severe neutropenia: a diagnostic approachWestern Journal of Medicine, 2000
- Hydroxychloroquine-Induced AgranulocytosisArchives of Dermatology, 1968